CAPR · Capricor Therapeutics Inc
United States · RS rating 56 · As of 2026-11-03
| Price | 8.24 USD |
|---|---|
| 1-day change | +13.8% |
| RS rating (overall / 1M / 3M / 12M) | 56 / 74 / 97 / 73 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 22 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -14.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +76.7% |
| Market cap (USD) | $2.0B |